UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
The loss of enjoyment of food and weight loss has shown to decrease the quality of life for cancer patients. Additionally, poor eating and weight loss affects patients’ overall health, making them increasingly tired and more likely to experience side effects from their cancer treatments. Some patients have to take lower doses of cancer-fighting treatments or stop using them altogether.
Anamorelin HCl, works by mimicking a naturally occurring substance in the body that causes increased appetite and weight gain.
This study is a randomized, double-blind, placebo-controlled study. "Placebo-controlled" means that some patients will take tablets containing the study drug and some patients will take tablets that do not contain any medication (placebo). "Randomized" means that you will be assigned to a treatment randomly, like flipping a coin. You have an equal chance of being assigned to receive the study drug or the placebo.
Study Identifier: 832183
Contact the research team to learn more about this study.